A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus

Show other versions (1)

Objective To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM). Methods This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. P...

Full description

Bibliographic Details
Main Authors:	AnneMarie Nardolillo, Michael P. Kane, Robert S. Busch, Jay Watsky, Robert A. Hamilton
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-01-01
Series:	Clinical Medicine Insights: Endocrinology and Diabetes
Online Access:	https://doi.org/10.4137/CMED.S18182

Similar Items

A Clinical Perspective of Canagliflozin in the Management of Type 2 Diabetes Mellitus
by: AnneMarie Nardolillo, et al.
Published: (2014-09-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-01-01)

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
by: Curtis Triplitt, et al.
Published: (2015-10-01)

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
by: Shusuke Yagi, et al.
Published: (2017-10-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
by: K M Prasanna Kumar, et al.
Published: (2016-01-01)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
by: K M Prasanna Kumar, et al.
Published: (2017-01-01)

The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
by: Vikri Haikal, et al.
Published: (2024-01-01)

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus
by: Hsiao-Huai Kuo, et al.
Published: (2023-12-01)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
by: Limin Wang, et al.
Published: (2023-10-01)

Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis
by: Yuying CHEN, Xiaodong LI, Yunzhao TANG, Daiqing LI
Published: (2022-05-01)

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
by: Juan J. Gorgojo-Martínez, et al.
Published: (2020-07-01)

Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014-08-01)

Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes
by: Skelley JW, et al.
Published: (2018-12-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
by: Davies MJ, et al.
Published: (2017-01-01)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
by: Manash P Baruah, et al.
Published: (2016-01-01)

Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus
by: W.T. Garvey, et al.
Published: (2017-11-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

Diabetic Ketoacidosis in A Patient with Type 2 Diabetes On Canagliflozin and Dexamethasone
by: Lisa D. Alexander, MD, et al.
Published: (2017-01-01)

The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus
by: Simo Liu, et al.
Published: (2024-01-01)

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
by: Kirandeep Kaur, et al.
Published: (2015-01-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013-11-01)

Patient profiling in diabetes and role of canagliflozin
by: Amblee A
Published: (2014-11-01)

Prolonged diabetic ketoacidosis associated with canagliflozin
by: Gordon Sloan, et al.
Published: (2018-06-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin
by: Gerlanc NM, et al.
Published: (2017-03-01)

Study on glycaemic control by canagliflozin and its effect on insulin resistance and plasma ketone in type 2 diabetes mellitus patients
by: J S Kumar, et al.
Published: (2019-01-01)

Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes
by: Li, J, et al.
Published: (2019)

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
by: Akira Sezai, et al.
Published: (2019-06-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
by: Daisuke Matsutani, et al.
Published: (2018-05-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming JW, et al.
Published: (2015-06-01)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
by: Seko Y, et al.
Published: (2018-11-01)

Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study
by: Pankaj Aneja, et al.
Published: (2019-01-01)

Canagliflozin - Beginning of the journey
by: Sunil Kumar Pandey, et al.
Published: (2014-01-01)